Clinical Trials Browser

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

NCT01336634 2022-04-04

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

Phase 2 Completed

177 enrolled 19 charts 2 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02083354 2022-02-01

Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma

Phase 2 Completed

77 enrolled 43 charts

Dermatologic

Melanoma, Neoplasms, Skin Neoplasms

NCT01072175 2019-07-05

Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212

Phase 2 Completed

430 enrolled 61 charts

Dermatologic

Melanoma, Neoplasms

NCT01376310 2019-02-19

GSK1120212 Rollover Study

Phase 2 Terminated

159 enrolled 9 charts

Tumor-Agnostic

Neoplasms

NCT02314143 2019-02-18

Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib

Phase 2 Terminated

48 enrolled 20 charts

Dermatologic

Melanoma, Neoplasms

NCT03543306 2018-06-01

Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation

Phase 2 Unknown

27 enrolled

Tumor-Agnostic

Neoplasms

NCT01328106 2017-12-12

Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma

Phase 2 Withdrawn

Dermatologic

Uveal Melanoma, Neoplasms

NCT01943864 2017-05-31

A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers

Phase 2 Completed

20 enrolled 27 charts

Gastrointestinal

Biliary Tract Neoplasms, Neoplasms

NCT00920140 2014-04-02

Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias

Phase 2 Completed

97 enrolled 23 charts

Other hematologic neoplasm

Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT01037127 2014-03-31

Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor

Phase 2 Completed

97 enrolled 18 charts

Dermatologic

Melanoma, Neoplasms

NCT01231581 2013-09-26

Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer

Phase 2 Completed

160 enrolled 14 charts

Tumor-Agnostic

Neoplasms

Clinical Trials

TAPUR

Pan Tumor Rollover Study

DRUP

Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations

Neo Trio

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma

Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212

GSK1120212 Rollover Study

Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib

Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation

Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma

A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers

Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias

Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor

Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer